DOCSLIB.ORG

Applied Proteomics in ‘One Health’

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Applied Proteomics in ‘One Health’ proteomes Review Applied Proteomics in ‘One Health’ Eleni I. Katsarou 1, Charalambos Billinis 1,2, Dimitrios Galamatis 3, George C. Fthenakis 1, George Th. Tsangaris 4 and Angeliki I. Katsafadou 2,* 1 Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece; [email protected] (E.I.K.); [email protected] (C.B.); [email protected] (G.C.F.) 2 Faculty of Public and One Health, University of Thessaly, 43100 Karditsa, Greece 3 Hellenic Agricultural Organization DIMITRA (ELGO DIMITRA), 54248 Thessaloniki, Greece; [email protected] 4 Proteomics Research Unit, Biomedical Research Foundation of Academy of Athens, 11527 Athens, Greece; [email protected] * Correspondence: [email protected] Abstract: ‘One Health’ summarises the idea that human health and animal health are interdependent and bound to the health of ecosystems. The purpose of proteomics methodologies and studies is to determine proteins present in samples of interest and to quantify changes in protein expression during pathological conditions. The objectives of this paper are to review the application of proteomics technologies within the One Health concept and to appraise their role in the elucidation of diseases and situations relevant to One Health. The paper develops in three sections. Proteomics Applications in Zoonotic Infections part discusses proteomics applications in zoonotic infections and explores the use of proteomics for studying pathogenetic pathways, transmission dynamics, diagnostic biomarkers and novel vaccines in prion, viral, bacterial, protozoan and metazoan zoonotic infections. Proteomics Applications in Antibiotic Resistance part discusses proteomics applications in mechanisms of resistance development and discovery of novel treatments for antibiotic resistance. Proteomics Citation: Katsarou, E.I.; Billinis, C.; Applications in Food Safety part discusses the detection of allergens, exposure of adulteration, Galamatis, D.; Fthenakis, G.C.; identification of pathogens and toxins, study of product traits and characterisation of proteins in food Tsangaris, G.T.; Katsafadou, A.I. safety. Sensitive analysis of proteins, including low-abundant ones in complex biological samples, Applied Proteomics in ‘One Health’. will be achieved in the future, thus enabling implementation of targeted proteomics in clinical settings, Proteomes 2021, 9, 31. https:// shedding light on biomarker research and promoting the One Health concept. doi.org/10.3390/proteomes9030031 Keywords: antibiotic resistance; biomarker; food safety; foodomics; One Health; pathogenesis; Academic Editor: Rainer Cramer proteomics; veterinary; zoonotic infection Received: 14 April 2021 Accepted: 25 June 2021 Published: 30 June 2021 1. Introduction Publisher’s Note: MDPI stays neutral The concept of ‘One Health’ was developed at the start of the current century. One with regard to jurisdictional claims in Health is the notion that the health of people, animals and ecosystems are strongly inter- published maps and institutional affil- connected. The definition summarises the idea that human health and animal health are iations. interdependent and bound to the health of the ecosystems in which they exist. The areas of work in which a One Health approach is particularly relevant, include the control of zoonoses, limiting bacterial resistance to antimicrobial agents and food safety [1] (Figure1). Controlling zoonotic pathogens at their animal source is the most effective way of pro- Copyright: © 2021 by the authors. tecting humans from the respective infections; consequently, strategies to control zoonotic Licensee MDPI, Basel, Switzerland. pathogens must be developed to prevent animal and human diseases. Further, prevention This article is an open access article of antibiotic resistance development at the animal level reduces the chances of dissemina- distributed under the terms and tion of resistant strains to humans from animal sources. Indeed, the connection between conditions of the Creative Commons animal health, food of animal origin and human health is more than evident for public Attribution (CC BY) license (https:// opinion and consumers [2]. creativecommons.org/licenses/by/ 4.0/). Proteomes 2021, 9, 31. https://doi.org/10.3390/proteomes9030031 https://www.mdpi.com/journal/proteomes Proteomes 2021, 9, x FOR PEER REVIEW 2 of 39 Proteomes 2021, 9, 31 between animal health, food of animal origin and human health is more than evident2 of for 38 public opinion and consumers [2]. FigureFigure 1. 1. SummarySummary diagram diagram of of the the applications applications of of proteomics methodologies in One Health. TheThe proteome proteome contains contains all all proteins proteins in in a cell a cell or ortissue tissue at any at any one onetime, time, thus thus taking taking into accountinto account all post-translational all post-translational modifications. modifications. The proteome The proteome is dynamic is dynamic and andchanges changes de- pendingdepending on onvarious various physiological physiological and and pathological pathological conditions conditions in in the the tissues tissues of of an an organ- organ- ism.ism. The The purpose purpose of of proteomics proteomics methodologie methodologiess and and studies studies is is to determine the proteins present in a samplesample ofof interestinterest and and to to quantify quantify changes changes in in protein protein expression expression during during various vari- ouspathological pathological conditions conditions [3]. [3]. ProteomicsProteomics includesincludes aa variety variety of technologies,of technologies, which which aredivided are divided in two in major twogroups: major groups:the gel-dependent the gel-dependent and the and gel-independent the gel-independent methods methods [4–7]. [4–7]. Nevertheless, Nevertheless, in both in both ap- approaches,proaches, protein protein identification identification is is performed performed with with mass mass spectrometryspectrometry (MS)(MS) [[6].6]. In In gel- gel- dependentdependent approaches, after isolationisolation ofof thethe proteinsproteins byby two-dimensional two-dimensional gel gel electrophore- electropho- resissis (2-DE), (2-DE), proteins proteins are are identified identified mainly mainly by by MALDI-TOF MALDI-TOF MS/MS MS/MS (matrix-assisted(matrix-assisted laser desorption/ionisation-time of flight tandem mass spectrometry). In gel-independent ap- desorption/ionisation-time of flight tandem mass spectrometry). In gel-independent ap- proaches, the protein content of a sample is identified by MS [8]. Further, proteomics can be proaches, the protein content of a sample is identified by MS [8]. Further, proteomics can applied as bottom-up or top-down approaches [9]. In bottom-up proteomics, pure proteins be applied as bottom-up or top-down approaches [9]. In bottom-up proteomics, pure pro- or complex protein mixtures are subjected to proteolytic cleavage and the peptide products teins or complex protein mixtures are subjected to proteolytic cleavage and the peptide are analysed by MS. In a top-down approach, intact protein ions or large protein fragments products are analysed by MS. Ιn a top-down approach, intact protein ions or large protein are subjected to gas phase fragmentation for MS analysis. Finally, data processing and fragments are subjected to gas phase fragmentation for MS analysis. Finally, data pro- evaluation are performed with bioinformatics approaches [10,11]. Detailed descriptions of cessing and evaluation are performed with bioinformatics approaches [10,11]. Detailed proteomics techniques that can be used in such studies have been presented before [12,13] descriptions of proteomics techniques that can be used in such studies have been pre- and are beyond the scope of this paper. sented before [12,13] and are beyond the scope of this paper. The objectives of this paper are to review the application of proteomics technologies The objectives of this paper are to review the application of proteomics technologies within the One Health concept and to appraise the role of these methodologies in the withinelucidation the One of diseases Health concept and situations and to relevantappraise tothe the role One of Healththese methodologies approach. in the elu- cidation of diseases and situations relevant to the One Health approach. 2. Proteomics Applications in Zoonotic Infections Infections of animal origin that can be transmitted to humans are termed ‘zoonotic infections’ and pose worldwide risks to public health. Other infections that are mainly transmitted from person to person may also circulate in animals or have an animal reservoir, and may cause serious health emergencies (Table S1). These risks increase with global- Proteomes 2021, 9, 31 3 of 38 isation, climate change and changes in human behaviour, giving pathogens numerous opportunities to colonise new territories and evolve into new forms [1]. 2.1. Prion Zoonotic Diseases Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative disor- ders characterised by the formation of amyloid aggregates, vacuolation of brain tissue and accumulation in the Central Nervous System (CNS) of a pathological conformer (PrPTSE) of the host-encoded cellular prion protein (PrPC). There are various human or animal prion diseases; the human diseases include kuru, Creutzfeldt–Jakob disease and variant Creutzfeldt–Jakob disease, Gerstmann–Straussler–Scheinker syndrome and fatal familial insomnia; the animal diseases include bovine spongiform encephalopathy, scrapie, chronic wasting disease,
Load more

Recommended publications
  • And Feline Infectious Peritonitis (FIP)
    Feline Coronavirus (FCoV) and Feline Infectious Peritonitis (FIP) VETERINARY GUIDE 10 What is Feline Coronavirus or FCoV? FCoV is a common and contagious virus which is passed in the faeces of cats. It is more commonly found in multi-cat households and does not affect other animals or people. How does a cat catch FCoV? FCoV is caught by inadvertently swallowing the virus, through contact with other cats, litter trays or soil where other cats have toileted. Exposure to faeces in the litter tray is the most common means of transmission. Forty per cent or more of cats will be infected with the virus at some time in their lives and most owners will be unaware of it. Nearly every cat that encounters the virus will become infected and most will remain healthy and the majority will clear the virus themselves. What problems does FCoV cause? Most cats do not display any sign of being infected with FCoV, although some cats get diarrhoea for a few days. These cats tend to shed the virus in their faeces for a few months and remain healthy. In a very small percentage of cats, the virus mutates and causes a fatal disease called feline infectious peritonitis (FIP). This is more likely to occur in multi-cat environments and can take weeks, months or occasionally years after the initial infection with FCoV to develop. If a cat clears FCoV and doesn’t develop FIP, is it then immune? Unfortunately not, a cat can become re-infected with FCoV again at any time and can be susceptible to it mutating and causing FIP.
    [Show full text]
  • Human Illness Caused by E. Coli O157:H7 from Food and Non-Food Sources
    FRI BRIEFINGS Human Illness Caused by E. coli O157:H7 from Food and Non-food Sources M. Ellin Doyle1*, John Archer2, Charles W. Kaspar1, and Ronald Weiss1 1Food Research Institute, University of Wisconsin–Madison, Madison, WI 53706 2Wisconsin Division of Public Health, Bureau of Communicable Diseases and Preparedness, Communicable Disease Epidemiology Section, Madison, WI 53702 Contents Introduction ...................................................................................................................................2 Epidemiology of E. coli O157:H7..................................................................................................2 Outbreak Data ........................................................................................................................2 Reservoirs of E. coli O157:H7 ..............................................................................................3 Cattle—the primary reservoir ........................................................................................3 Other ruminants .............................................................................................................4 Other animals .................................................................................................................4 Transport Hosts......................................................................................................................4 Routes of Human Infection ....................................................................................................5
    [Show full text]
  • Gut Microbiome, Antibiotic Use, and Immunotherapy Responsiveness in Cancer
    309 Editorial Commentary Page 1 of 4 Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer Jarred P. Reed, Suzanne Devkota, Robert A. Figlin Cedars-Sinai Medical Center, Los Angeles, CA, USA Correspondence to: Robert A. Figlin. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Saperstein Critical Care Tower, C 2003, Los Angeles, CA 90048, USA. Email: [email protected]. Provenance: This is an invited article commissioned by the Section Editor Dr. Xiao Li (Department of Urology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China). Comment on: Tinsley N, Zhou C, Tan G, et al. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. Oncologist 2019. [Epub ahead of print]. Submitted Sep 27, 2019. Accepted for publication Oct 10, 2019. doi: 10.21037/atm.2019.10.27 View this article at: http://dx.doi.org/10.21037/atm.2019.10.27 Immune checkpoint inhibitors (ICIs) have transformed undergoing ICI treatment were reviewed for antibiotic the treatment of solid malignancies, but responses are exposure occurring within the time period two weeks heterogeneous with benefit generally limited to only before and six weeks after initiation of ICI therapy. Ninety- a fraction of patients. A number of factors have been two patients (32%) in the study received antibiotics. hypothesized to contribute to variability in ICI efficacy. Univariate analyses were performed to assess for significant Among these, a growing body of evidence points to a associations between patient characteristics and outcomes. critical role for the commensal gut microbiome, the Progression-free survival (PFS) was found to correlate with complex ecosystem of microorganisms living together antibiotic exposure, performance status, and comorbidity.
    [Show full text]
  • How Do Pathogenic Microorganisms Develop Cross-Kingdom Host Jumps? Peter Van Baarlen1, Alex Van Belkum2, Richard C
    Molecular mechanisms of pathogenicity: how do pathogenic microorganisms develop cross-kingdom host jumps? Peter van Baarlen1, Alex van Belkum2, Richard C. Summerbell3, Pedro W. Crous3 & Bart P.H.J. Thomma1 1Laboratory of Phytopathology, Wageningen University, Wageningen, The Netherlands; 2Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands; and 3CBS Fungal Biodiversity Centre, Utrecht, The Netherlands Correspondence: Bart P.H.J. Thomma, Abstract Downloaded from https://academic.oup.com/femsre/article/31/3/239/2367343 by guest on 27 September 2021 Laboratory of Phytopathology, Wageningen University, Binnenhaven 5, 6709 PD It is common knowledge that pathogenic viruses can change hosts, with avian Wageningen, The Netherlands. Tel.: 10031 influenza, the HIV, and the causal agent of variant Creutzfeldt–Jacob encephalitis 317 484536; fax: 10031 317 483412; as well-known examples. Less well known, however, is that host jumps also occur e-mail: [email protected] with more complex pathogenic microorganisms such as bacteria and fungi. In extreme cases, these host jumps even cross kingdom of life barriers. A number of Received 3 July 2006; revised 22 December requirements need to be met to enable a microorganism to cross such kingdom 2006; accepted 23 December 2006. barriers. Potential cross-kingdom pathogenic microorganisms must be able to First published online 26 February 2007. come into close and frequent contact with potential hosts, and must be able to overcome or evade host defences. Reproduction on, in, or near the new host will DOI:10.1111/j.1574-6976.2007.00065.x ensure the transmission or release of successful genotypes.
    [Show full text]
  • What Is One Health?
    What is One Health? “One Health” has been defined many ways. At its core, One Health fosters a collaborative approach to issues that intersect human, animal and environmental health. Although One Health is not a new concept, it has become more important in recent years. Interactions among people, animals, and the environment continue to change. The expansion of human and animal populations, changes in climate and land use, and increased international travel and trade provide opportunities for disease spread. Approximately 75% of recently emerging infectious diseases affecting humans are diseases of animal origin; approximately 60% of all human pathogens are zoonotic. Zoonotic diseases are those that are spread between people and animals. One Health obviously includes the health professions. But, it also includes wildlife specialists, anthropologists, economists, environmentalists, behavioral scientists, and sociologists, among others. One Health embraces the idea that complex problems at the human-animal-environmental interface can best be solved through multidisciplinary communication, cooperation, and collaboration. One Health is increasingly being acknowledged by national and international institutions as the most constructive approach to address complex issues at the animal-human-environmental interface. The History of One Health A German scholar from the mid 1800’s, Rudolf Virchow, who came from a farming family, was an early proponent of One Health. He said, “Between animal and human medicine there is no dividing line—nor should there be. The object is different but the experience obtained constitutes the basis of all medicine.” During the last 3 decades, approximately 75 percent of emerging infectious diseases among humans have been zoonotic diseases, which can be transmitted from animals to people.
    [Show full text]
  • One Health & Zoonotic Diseases Chapter
    One Health & Zoonotic Diseases Chapter What are zoonotic diseases? Zoonotic diseases, or zoonoses, are diseases that Introduction can be spread between animals, people, or produce. People and animals have been living closely together Zoonoses are one example of how the health of for centuries. We continue to interact often with people is related to the health of animals and animals—pets, livestock, small stock, recreational, environment. Some of these diseases you may be zoo and wild animals. The environments we share as familiar with or have heard of, such as E. coli, animals and humans are also important. Constantly influenza, or rabies. Others, including Q fever, changing conditions such as the weather, natural toxoplasmosis, or psittacosis, may be new to you. disasters, and human habitat developments There are even some diseases that scientists do not expanding into farm/ranch lands and wildlife know much about because they are so new or are habitats link the environment people, and animals not seen very often in the United States. These are together. People, animals, and insects frequently called emerging diseases. interact and share environments, and because of this, diseases are passed back and forth. Some old Zoonotic diseases can affect people and animals disease reemerge, and new diseases can appear. Our differently. In some cases, the disease can cause efforts to keep food and water sources safe, protect sickness in both animals and people. Sometimes, the environment, and safeguard people and animals animals are just ‘carriers’ of the disease-causing from diseases must also overlap. germ, but don’t get sick. The germs that cause zoonotic diseases can be viruses, bacteria, fungi, What is One Health? or parasites.
    [Show full text]
  • WHO GUIDELINES for the Treatment of Treponema Pallidum (Syphilis)
    WHO GUIDELINES FOR THE Treatment of Treponema pallidum (syphilis) WHO GUIDELINES FOR THE Treatment of Treponema pallidum (syphilis) WHO Library Cataloguing-in-Publication Data WHO guidelines for the treatment of Treponema pallidum (syphilis). Contents: Web annex D: Evidence profiles and evidence-to-decision frameworks - Web annex E: Systematic reviews for syphilis guidelines - Web annex F: Summary of conflicts of interest 1.Syphilis – drug therapy. 2.Treponema pallidum. 3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154980 6 (NLM classification: WC 170) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/ copyright_form/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Feline—Aerosol Transmission
    Feline—Aerosol Transmission foreign animal disease zoonotic disease Anthrax (Bacillus anthracis) Aspergillus spp. Bordetella bronchiseptica Calicivirus (FCV) Canine Parvovirus 2 Chlamydophila felis Coccidioides immitis Cryptococcus neoformans Feline Distemper (Feline Panleukopenia, Feline Parvovirus) Feline Infectious Peritonitis (FIP) Feline Viral Rhinotracheitis (FRV) Glanders (Burkholderia mallei) Hendra Virus Histoplasma capsulatum Melioidosis (Burkholderia pseudomallei) Nipah Virus Plague (Yersinia pestis) Pneumocystis carinii Q Fever (Coxiella burnetii) Tuberculosis (Mycobacterium spp.) www.cfsph.iastate.edu Feline—Oral Transmission foreign animal disease zoonotic disease Anthrax (Bacillus anthracis) Babesia spp. Botulism (Clostridium botulinum) Campylobacter jejuni Canine Parvovirus 2 Coccidiosis (Isospora spp.) Cryptosporidium parvum Escherichia coli (E. coli) Feline Coronavirus (FCoV) Feline Distemper (Feline Panleukopenia, Feline Parvovirus) Feline Immunodefi ciency Virus (FIV) Feline Infectious Peritonitis (FIP) Feline Leukemia Virus (FeLV) Giardia spp. Glanders (Burkholderia mallei) Helicobacter pylori Hookworms (Ancylostoma spp.) Leptospirosis (Leptospira spp.) Listeria monocytogenes Melioidosis (Burkholderia pseudomallei) Pseudorabies Roundworms (Toxocara spp.) Salmonella spp. Strongyles (Strongyloides spp.) Tapeworms (Dipylidium caninum, Echinococcus spp.) Toxoplasma gondii Tuberculosis (Mycobacterium spp.) Tularemia (Francisella tularensis) Whipworms (Trichuris campanula) www.cfsph.iastate.edu
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • One Health Legislation: Contributing to Pandemic Prevention Through Law
    July 2020 One Health legislation: Contributing to pandemic prevention through law “AN OUNCE OF PREVENTION IS WORTH A POUND OF CURE” BENJAMIN FRANKLIN INTRODUCTION The COVID-19 pandemic and other emerging infectious diseases, as well as the continuing threat of antimicrobial resistance (AMR), are reminding us of the close connections between human, animal and environmental health and the urgent need to address them in a holistic manner. Among newly discovered or emerging infectious diseases (EIDs), 75 percent are zoonotic (i.e. transmitted from animals to humans) (Taylor, Latham and Woolhouse, 2001). The unregulated expansion of livestock farming encroaches upon pristine habitats, pushing domestic animals, humans and wildlife into closer and more frequent contact, creating the same tinderbox for disease in animals as they do in humans (FAO, 2011a). Deforestation and other land use changes have an important part in the emergence of disease (Wilcox and Ellis, 2006). To address these increasing and inter-linked health challenges, while ensuring the biological integrity of the planet, it will be important to strengthen inter-disciplinary and cross-sectoral approaches that address not only disease prevention but also biodiversity conservation, climate change, and sustainable development overall (Wildlife Conservation Society, 2019). The Sustainable Development Goals (SDGs), in particular SDG 3 (“Ensure healthy lives and promote well-being for all at all ages”) and SDG 15 (“Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, combat desertification, and halt and reverse land degradation and halt biodiversity loss”) provide a unique opportunity to break the silos and to work in a coordinated manner on human, animal and environmental health.
    [Show full text]
  • Differences in Innate Immune Response Between Man and Mouse
    Institute of Medical Physics and Biophysics Medical Department, Leipzig University Author Manuscript © 2014. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ Published in final edited form as: Critical Reviews™ in Immunology, 2014; 34:433-54. Available at: http://dx.doi.org/ 10.1615/CritRevImmunol.2014011600. DIFFERENCES IN INNATE IMMUNE RESPONSE BETWEEN MAN AND MOUSE Josefin Zschaler 1,2,*, Denise Schlorke 1,2,* & Juergen Arnhold 1,2 1 Institute for Medical Physics and Biophysics, Medical Faculty, Leipzig University, Leipzig, Germany 2 Translational Centre for Regenerative Medicine (TRM), Leipzig University, Leipzig, Germany * Both authors contributed equally to this work. Abstract Mouse strains are frequently used to model human disease states, to test the efficiency of drugs and therapeutic principles. However, the direct translation of murine experimental data to human pathological events often fails due to sufficient differences in the organization of the immune system of both species. Here we give a short overview of the principle differences between mice and humans in defense strategies against pathogens and mechanisms involved in response to pathogenic microorganisms and other activators of the immune system. While in human blood mechanisms of immune resistance are highly prevailed, tolerance mechanisms dominate for the defense against pathogenic microorganisms in mouse blood. Further on, species-related differences of immune cells mainly involved in innate immune response as well as differences to maintain oxidative homeostasis are also considered. A number of disease scenarios in mice are critically reflected for their suitability to serve as a model for human pathologies.
    [Show full text]
  • The Public Health Impact of Prion Diseases1
    10 Feb 2005 13:10 AR AR238-PU26-08.tex AR238-PU26-08.sgm LaTeX2e(2002/01/18) P1: IBD 10.1146/annurev.publhealth.26.021304.144536 Annu. Rev. Public Health 2005. 26:191–212 doi: 10.1146/annurev.publhealth.26.021304.144536 Copyright ©c 2005 by Annual Reviews. All rights reserved First published online as a Review in Advance on December 8, 2004 THE PUBLIC HEALTH IMPACT OF PRION DISEASES1 Ermias D. Belay and Lawrence B. Schonberger Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333; email: [email protected] KeyWords transmissible spongiform encephalopathy, Creutzfeldt-Jakob disease, variant Creutzfeldt-Jakob disease, bovine spongiform encephalopathy, chronic wasting disease ■ Abstract Several prion disease–related human health risks from an exogenous source can be identified in the United States, including the iatrogenic transmission of Creutzfeldt-Jakob disease (CJD), the possible occurrence of variant CJD (vCJD), and potential zoonotic transmission of chronic wasting disease (CWD). Although cross- species transmission of prion diseases seems to be limited by an apparent “species barrier,” the occurrence of bovine spongiform encephalopathy (BSE) and its transmis- sion to humans indicate that animal prion diseases can pose a significant public health risk. Recent reports of secondary person-to-person spread of vCJD via blood products and detection of vCJD transmission in a patient heterozygous at codon 129 further illustrate the potential public health impacts of BSE. INTRODUCTION by IRMO/Information Center on 03/14/05. For personal use only. Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of animal and human brain diseases that are uniformly fatal and often characterized by a long incubation period and a multifocal neuropathologic picture of neuronal loss, spongiform changes, and astrogliosis (3).
    [Show full text]